// COMPANY
Lycia Therapeutics
SECTOR BIOTECHMENTIONS 1LAST SEEN OCTOBER 6, 2026
// RECENT MENTIONS
// SIGNALS
1 SIGNAL
01
funding·Axios Pro Rata·OCTOBER 6, 2026
“Lycia Therapeutics, an SF biotech targeting extracellular proteins... The Phase 1 company plans to list on the Nasdaq (LYCA) and raised over $330m.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.